Farmácia/Notícias da Indústria

M-A de estudos randomizados | Associação entre vacinação contra influenza e risco cardiovascular.

4 Mai, 2022 | 13:55h

Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis – JAMA Network Open

 

Comentário no Twitter

In this meta-analysis, seasonal flu vaccine was associated with a 34% reduced risk of major adverse cardiovascular events in 1 year, with the biggest difference in patients with recent acute coronary syndrome. @WCHResearch @PMunkCardiacCtr https://t.co/SPrXNfMQJS

— JAMA Network Open (@JAMANetworkOpen) April 29, 2022

 

---

Revisão | Equianalgesia, troca de opioides e associação de opioides em diferentes ambientes clínicos.

4 Mai, 2022 | 13:43h

Equianalgesia, opioid switch and opioid association in different clinical settings: a narrative review – European Review for Medical and Pharmacological Sciences

---

Pfizer afirma que o tratamento de COVID com Paxlovid não previne infecção domiciliar.

3 Mai, 2022 | 16:46h

Pfizer says COVID treatment Paxlovid fails to prevent infection of household members – Reuters

 

Comentário no Twitter

Pfizer Inc on Friday said a large trial found that its COVID-19 oral antiviral treatment Paxlovid was not effective at preventing coronavirus infection in people living with someone who had been exposed to the virus. https://t.co/95zphEYaxc

— Reuters Health (@Reuters_Health) April 29, 2022

 

---

Estudo randomizado | Fentermina/topiramato para tratamento de obesidade na adolescência.

3 Mai, 2022 | 16:45h

Phentermine/Topiramate for the Treatment of Adolescent Obesity – NEJM Evidence

 

Comentário no Twitter

This RCT evaluated phentermine/topiramate in adolescents ages 12 to <17 yrs with high BMIs over a 56 week period. At both mid- and top-doses, treatment significantly reduced BMI and waist circumference compared to placebo. https://t.co/HbCZOAlZPf@PedsEndoSociety #PedsEndo2022 pic.twitter.com/nB5juqxyA0

— NEJM Evidence (@NEJMEvidence) April 30, 2022

 

---

Estudo randomizado | Curso antibiótico com duração estendida vs. padrão em crianças menores de 5 anos de idade com pneumonia adquirida na comunidade em ambientes de alto risco.

2 Mai, 2022 | 14:06h

Extended Versus Standard Antibiotic Course Duration in Children <5 Years of Age Hospitalized With Community-acquired Pneumonia in High-risk Settings: Four-week Outcomes of a Multicenter, Double-blind, Parallel, Superiority Randomized Controlled Trial – The Pediatric Infectious Disease Journal

Conteúdos relacionados:

Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial – JAMA Pediatrics

Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians – Annals of Internal Medicine

Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial – JAMA Pediatrics

Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial – JAMA

Treatment of UTIs in Infants <2 Months: A Living Systematic Review – Hospital Pediatrics

Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial – JAMA

Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial – Clinical Infectious Diseases

Efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults: A systematic review and meta-analysis – Antimicrobial Agents and Chemotherapy

 

Comentário no Twitter

15th RCT of short course therapy for CAP just published, this one another peds study (3 mo to <5 yr). 5-6 d vs. 14 days. Guess what the outcome was??? Updated tables will be tweeted out soon!@ABsteward @DoctorRachael @medrants https://t.co/br4WAEXAzJ

— Brad Spellberg (@BradSpellberg) April 28, 2022

 

---

Revisão | Compreendendo a segurança da vacina e as funções do FDA e do CDC.

2 Mai, 2022 | 14:04h

Understanding Vaccine Safety and the Roles of the FDA and the CDC – New England Journal of Medicine

 

Comentário no Twitter

Development and public acceptance of vaccines are crucial for disease control. Cody Meissner, M.D., reviews the process of evaluating vaccine safety and efficacy and factors that advisory bodies consider in making recommendations. https://t.co/ITqpGthoac pic.twitter.com/HTkyAaWvDO

— NEJM (@NEJM) April 28, 2022

 

---

OMS revela a chocante extensão da propaganda de fórmulas lácteas.

2 Mai, 2022 | 14:00h

Comunicado de imprensa: WHO reveals shocking extent of exploitative formula milk marketing – World Health Organization

Relatório: Scope and impact of digital marketing strategies for promoting breastmilk substitutes – World Health Organization

Conteúdo relacionado: More than half of parents and pregnant women exposed to aggressive formula milk marketing – WHO, UNICEF – World Health Organization

 

Comentário no Twitter (fio – clique para saber mais)

🆕 WHO report reveals shocking extent of exploitative formula milk marketing

The formula milk industry, valued at US$55 billion, is paying social media platforms & influencers to gain direct access to pregnant women & mothers.#EndExploitativeMarketing
👉https://t.co/0dciNxB0fQ pic.twitter.com/hhAnyp0ueH

— World Health Organization (WHO) (@WHO) April 29, 2022

 

---

Covid-19: qual é a evidência para o uso do antiviral Paxlovid?

29 Abr, 2022 | 15:16h

Covid-19: What is the evidence for the antiviral Paxlovid? – The BMJ

Conteúdos relacionados:

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

A living WHO guideline on drugs for covid-19 – The BMJ

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

---

Especialistas temem que os EUA padronizem o reforço anual de vacinas contra Covid sem dados suficientes.

29 Abr, 2022 | 15:11h

Experts fear U.S. may default to annual Covid boosters without sufficient data – STAT

 

Comentário no Twitter

Vaccine experts are concerned the U.S. may be sleepwalking into a policy of recommending annual Covid-19 vaccine boosters — without having generated the evidence to show they are actually needed. https://t.co/3TiNZvP0HY

— STAT (@statnews) April 26, 2022

 

---

Revisão das evidências e guia prático de uso clínico | Inibidores do cotransportador sódio-glicose 2 na insuficiência cardíaca aguda.

29 Abr, 2022 | 14:58h

Sodium-glucose Co-transporter 2 Inhibitors in Acute Heart Failure: A Review of the Available Evidence and Practical Guidance on Clinical Use – Reviews in Cardiovascular Medicine

 

Comentário no Twitter

#RCM – Vol. 23 No. 4
📑Review
Sodium-glucose Co-transporter 2 Inhibitors in Acute Heart Failure: A Review of the Available Evidence and Practical Guidance on Clinical Use#SGLT2Inhibitor #HeartFailure

Fulltext:https://t.co/Y997Js75GG pic.twitter.com/61gieE7Mcv

— Reviews in Cardiovascular Medicine (@RCMjournal) April 27, 2022

 

---